<乌鸦传媒>Pomalidomide Cuts Severe Epistaxis in Genetic Bleeding Disorder 24 weeks of daily treatment significantly reduced recurrent nosebleeds in HHT trial Dec 13, 2023
<乌鸦传媒>Early Detection Is Key to Higher Cure Rates in Ovarian Cancer "We are not aware of precancer stages for ovarian cancer" Dec 13, 2023
<乌鸦传媒>Four Drugs Top Three for Upfront Treatment of Multiple Myeloma Adding anti-CD38 antibodies boosts response and PFS, but timing, sequencing, cost questioned Dec 13, 2023
<乌鸦传媒>One in Five BRCA-Positive Breast Cancer Patients Able to Conceive Disease-free survival comparable between patients who did and did not become pregnant Dec 12, 2023
<乌鸦传媒>Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia Investigational drug revumenib now under review at FDA for KMT2A-rearranged disease Dec 12, 2023
<乌鸦传媒>Novel Monoclonal Antibody Reduces Bleeds in Hemophilia A and B Marstacimab reduced the annualized bleeding rate versus on-demand, prophylactic treatments Dec 12, 2023
<乌鸦传媒>Ruxolitinib Combinations Reduce Spleen Volume in Myelofibrosis Combos with navitoclax or pelabresib led to more patients achieving reductions Dec 12, 2023
<乌鸦传媒>KEYNOTE-A18 Data Are 'Practice-Changing' for Cervical Cancer Domenica Lorusso details the importance of modern radiotherapy in this regimen Dec 12, 2023
<乌鸦传媒>Axatilimab Shows Efficacy in Recurrent/Refractory GVHD Highest overall response rate and least toxicity seen with lowest dose Dec 11, 2023
<乌鸦传媒>MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia No advantage for MRD-negative patients in first remission after induction, regardless of FLT3 ITD Dec 11, 2023
<乌鸦传媒>A Closer Look at the Approval of CRISPR/Cas9 Gene Therapy for Sickle Cell Disease This landmark event brings up broader considerations and implications for other diseases Dec 11, 2023
<乌鸦传媒>ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission Better 2-year PFS, OS, but not applicable to primary refractory disease Dec 10, 2023
<乌鸦传媒>Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients Time-limited approach based on MRD response outperforms FCR, but U.S. applicability unclear Dec 10, 2023
<乌鸦传媒>Emicizumab Safe, Effective, in Infants With Hemophilia A More than half of children in study had no treated bleeds at follow-up of more than 100 weeks Dec 10, 2023
<乌鸦传媒>Add-On Inavolisib Ups PFS in PIK3CA-Mutated Breast Cancer Triplet therapy may surpass benefits of current "pretty active doublet" therapy, expert says Dec 10, 2023
<乌鸦传媒>Lovo-Cel 'Life-Changing, Transformative' in Sickle Cell Disease Near complete resolution of pain events in patients, including adolescents Dec 10, 2023
<乌鸦传媒>Bispecific Antibody Combination Active in Metastatic HR+/HER2+ Breast Cancer Two-thirds of patients progression free at 6 months with zanidatamab, palbociclib, fulvestrant Dec 10, 2023
<乌鸦传媒>Grappling With Our Deadliest Cancer Here are essential steps to improve lung cancer screening Dec 10, 2023
<乌鸦传媒>Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials Survival 75% worse compared with outcomes seen in registrational studies Dec 10, 2023
<乌鸦传媒>Completely Oral Regimen Effective, Feasible in APL 97% of patients alive and relapse-free at 3 years Dec 10, 2023
<乌鸦传媒>Less-Frequent Surveillance Mammo Feasible in Older Breast Cancer Survivors No difference for survival outcomes for annual versus around every 2 years Dec 09, 2023
<乌鸦传媒>AI and Breast Cancer Screening; Cancer After Treatment for Sickle Cell Also in TTHealthWatch: mail-in cervical cancer screening kits Dec 09, 2023 podcast
<乌鸦传媒>Bilateral Mastectomy Not Tied to Better Survival in BRCA1-Positive Breast Cancer However, the surgery did reduce risk of contralateral breast cancer Dec 09, 2023
<乌鸦传媒>Is Omitting Radiation Therapy in Low-Risk Breast Cancer a Good IDEA? Local recurrence rate of 1% at 5 years in women ages 50-69 with genomically low-risk disease Dec 08, 2023
<乌鸦传媒>EUS-Guided Gastroenterostomy Better Option for Cancer-Related Duodenal Blockages However, technique and technology are not widespread Dec 08, 2023
<乌鸦传媒>Study Supports ADC as a New Option for Endocrine-Resistant Metastatic Breast Cancer Datopotamab deruxtecan was safe and boosted quality of life Dec 08, 2023
<乌鸦传媒>Maintenance Pembrolizumab-Olaparib Fails to Boost Survival in TNBC But better safety profile versus continued pembrolizumab plus chemotherapy Dec 08, 2023
<乌鸦传媒>Milestone Gene Therapies for Sickle Cell Disease Greenlit by FDA Casgevy and Lyfgenia approved for one-time treatment of sickle cell disease Dec 08, 2023
<乌鸦传媒>Study 'Underscores' Value of Early Fertility Counseling for Breast Cancer Patients Younger age, embryo/oocyte cryopreservation at diagnosis tied to an increased chance of pregnancy Dec 08, 2023
<乌鸦传媒>More Awareness Needed of Heart Events Tied to Breast Cancer Drugs, Experts Say Myriad clinical manifestations of cardiotoxicity must be diagnosed, treated promptly Dec 08, 2023
<乌鸦传媒>Adding Immunotherapy to Neoadjuvant Chemo Boosts pCR in HR-Positive Breast Cancer Promising early results with pembrolizumab, nivolumab but event-free survival data still pending Dec 07, 2023
<乌鸦传媒>GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients Association strongest in patients with overweight, obesity Dec 07, 2023
<乌鸦传媒>Detecting Ovarian Cancer Early; Allergy Med for NSCLC? Bad News for Anti-TIGIT Drug News, features, and commentary about cancer-related issues Dec 07, 2023
<乌鸦传媒>The Treatment Landscape for Cervical Cancer Has Changed Our experts discuss the impact of new options and approaches available in the field Dec 07, 2023 video
<乌鸦传媒>No Benefit to Adjuvant-Only Immunotherapy in Early TNBC Neoadjuvant administration of immunotherapy remains the preferred approach Dec 07, 2023
<乌鸦传媒>De-Escalating Breast Cancer Treatment Feasible After Response to Neoadjuvant Chemo Study showed no increase in disease progression when omitting regional nodal irradiation Dec 07, 2023
<乌鸦传媒>Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer Adding agent to T-DM1 resulted in 2-month progression-free survival improvement Dec 06, 2023
<乌鸦传媒>FDA Approves Oral Factor B Inhibitor for Paroxysmal Nocturnal Hemoglobinuria Iptacopan tops C5 Inhibitors for sustained hemoglobin levels, eliminating need for transfusion Dec 06, 2023
<乌鸦传媒>TULSA Effective in Controlling Prostate Cancer Long-Term At 5 years, median PSA was reduced by 90% Dec 05, 2023
